Search Results

You are looking at 81 - 90 of 1,569 items for :

  • "NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma

Presented by: Craig M. Horbinski and L. Burt Nabors

, Northwestern University and Northwestern Memorial Hospital, and member of the NCCN Guidelines Panel for Central Nervous System (CNS) Cancers. At the NCCN 2023 Annual Conference, together with L. Burt Nabors, MD, Vice Chair for Research of Neurology and

Full access

Modification and Implementation of NCCN Guidelines™ on Hepatobiliary Cancers in the Middle East and North Africa Region

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

T he 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ) addresses 4 main tumor groups

Full access

Head and Neck Cancers, Version 2.2013

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, David E. Schuller, Jatin P. Shah, Sharon Spencer, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

: Integrate into professional practice the updates to NCCN Guidelines for Head and Neck Cancers Describe the rational behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers NCCN Categories of Evidence and

Full access

Attitudes Toward and Use of Cancer Management Guidelines in a National Sample of Medical Oncologists and Surgeons

Reshma Jagsi, Grace Huang, Kent Griffith, Brian J. Zikmund-Fisher, Nancy K. Janz, Jennifer J. Griggs, Steven J. Katz, and Sarah T. Hawley

use of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) specifically, given prior work suggesting that these were the most commonly used cancer management guidelines. 5 Respondents were first asked if they knew that NCCN provides

Full access

Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma

Hugo J.A. Adams and Thomas C. Kwee

Full access

Uterine Sarcoma, Version 1.2016

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Uterine Sarcoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Uterine Sarcoma NCCN

Full access

Trends in Female Representation on NCCN Guideline Panels

Pranammya Dey, Angela K. Green, Michael Haddadin, Peter B. Bach, and Aaron P. Mitchell

from NCCN Member Institutions. Previous work has suggested that female representation on NCCN Guidelines Panels tends to reflect the underlying proportion of accomplished female researchers working in each tumor type. 2 Throughout academic medicine

Full access

Ovarian Cancer, Version 3.2012

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

NCCN Guidelines Insights : Ovarian Cancer,Version 3.2012 Version 3.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the

Full access

Soft Tissue Sarcoma, Version 2.2014

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, and Hema Sundar

: Integrate into professional practice the updates to NCCN Guidelines for Soft Tissue Sarcoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Soft Tissue Sarcoma NCCN Categories of Evidence and Consensus

Full access

Kidney Cancer, Version 2.2014

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

to: Integrate into professional practice the updates to NCCN Guidelines for Kidney Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Kidney Cancer NCCN Categories of Evidence and